trastuzumab   Click here for help

GtoPdb Ligand ID: 5082

Synonyms: D5v8 | Herceptin® | R-597
Approved drug
trastuzumab is an approved drug (FDA (1998), EMA (2000))
Compound class: Antibody
Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon Approved in India, FDA 2017, EMA 2018 (Ogivri)Breast cancer
trastuzumab-pkrb; CT-P6Herzuma; CredimaCelltrionApproved in S Korea, EMA & FDA 2018Breast cancer
trastuzumab-dttb; SB3OntruzantSamsung BioepisApproved (EMA 2017, FDA 2019)All approved indications of the reference product
trastuzumab-beta; trastuzumab-anns; ABP-980 [3]KanjintiAmgen/AllerganApproved (EMA 2018, FDA 2019)All approved indications of the reference product
trastuzumab-qyyp; PF-05280014TrazimeraPfizerApproved (FDA 2019; see REFLECTIONS B327-02 trial NCT01989676)All approved indications of the reference product
trastuzumab-strf; HLX02Zercepac; HercessiShanghai Henlius Biotech; Accord HealthcareApproved (EMA 2020, FDA 2024)EMA approved to treat HER2 positive metastatic breast cancer; FDA approval indicated for breast cancer plus HER2-overexpressing gastric or gastroesophageal junction adenocarcinomas
trastuzumab; EG12014HerwendaSandozApproved (EMA 2023)Early breast cancer and metastatic gastric cancer
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

References
1. Hudziak RM, Shepard HM, Ullrich A. (1989)
Method of treating tumor cells by inhibiting growth factor receptor function.
Patent number: WO1989006692. Assignee: Genentech Inc. Priority date: 12/01/1988. Publication date: 27/07/1989.
2. Mitri Z, Constantine T, O'Regan R. (2012)
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
Chemother Res Pract, 2012: 743193. [PMID:23320171]
3. Paplomata E, Nahta R. (2018)
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Expert Opin Biol Ther, 18 (3): 335-341. [PMID:29350568]